Why monitoring Barrett's esophagus matters
Barrett's esophagus affects about
1 in 17
people in the United States1
Esophageal cancer affects
1 in 40
BE patients who might progress over 5 years2
Not all BE risk is the same
Different people with the same type of BE may have varying levels of cancer risk.
- Low-risk individuals gain peace of mind knowing that their personal risk of developing esophageal cancer is low.
- High-risk individuals that are identified early allow for intervention and treatment to prevent esophageal cancer.
.jpg)
What is TissueCypher, and how does it help?
TissueCypher is a specialized test that analyzes BE tissue for signs of future progression to cancer. It is done on tissue taken during your endoscopy procedure.
A TissueCypher test report will include the following results:
The risk classification tells you which category you are in based on your risk of progression: low risk, intermediate risk, or high risk.
The risk score tells you your risk on a scale of 0-10. The lower the number, the lower your risk of progression.
The 5-year personal risk of progression tells you your likelihood of progressing to cancer within 5 years of your biopsy.
.jpg)
What you can expect
.png)
Your healthcare professional orders the TissueCypher test.
Castle Biosciences will work with your healthcare professional's laboratory to obtain a tissue sample from your original biopsy.
Our laboratory analyzes your tissue sample with our TissueCypher test.
Test results are sent to your healthcare professional so that your individual results can be discussed and used to determine next steps.
What to expect
Your healthcare professional orders the TissueCypher test.
Castle Biosciences will work with your healthcare professional's laboratory to obtain a tissue sample from your original biopsy.
Our laboratory analyzes your tissue sample with our TissueCypher test.
Test results are sent to your healthcare professional so that your individual results can be discussed and used to determine next steps.
What to expect
Take the next step- your voice matters in your care
Wherever you are in your journey with Barrett's esophagus, you deserve clarity. Ask your clinician about TissueCypher and take the next step toward informed, confident care.
Get connected with a clinician
.jpg)
Discuss the test with your clinician
.png)
Frequently asked questions
Castle Biosciences is committed to providing high-quality molecular testing to all patients. We do not want financial concerns to be a barrier to patients accessing critical healthcare information. We will work with all insurance providers, including Medicare, Medicaid, commercial insurers, and Veterans Affairs (VA) to secure payment coverage for our testing.
Please call our customer service staff at 866-788-9007 Option 1.
TissueCypher provides a risk score and probability of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) within five years. In a recent study by the Mayo Clinic, TissueCypher was shown to independently predict increased risk of progression to HGD/EAC and was also shown to be a stronger predictor of progression than other traditional risk factors like age, sex, segment length, and even expert pathology.3
Multiple published studies have shown that TissueCypher has a higher positive predictive value than these traditional risk factors (e.g., patients who receive a TissueCypher high-risk score progress at a higher rate than patients with confirmed low-grade dysplasia).
This type of testing is an emerging, fast-growing field, so your doctor may not be aware of all the tests that are now available to guide disease management decisions. If your doctor is interested in more information beyond our test descriptions on this website, please refer them to Castle Biosciences' customer service at 866-788-9007 Option 1.
Only a physician, physician assistant, or nurse practitioner can order a TissueCypher test.
Feel empowered on your journey — ask your clinician about TissueCypher today
References
- Hayeck TJ, Kong CY, Spechler SJ et al. The prevalence of Barrett’s esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus. 2010 Aug;23(6):451-7. doi: 10.1111/j.1442-2050.2010.01054.x.
- Sharma P. Barrett Esophagus: A Review. JAMA. 2022;16;328(7):663-671.
- Iyer PG, Codipilly DC, Chandar AK, et al. Prediction of Progression in Barrett's Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies. Clinical Gastroenterology and Hepatology. 2022;20(12):2772-2779.e8. doi:10.1016/j.cgh.2022.02.033